Quick Facts

• May provide relief from: Symptoms of inflammation and pain.
• Therapeutic domains: Osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis.
• Also used for: Symptomatic management of painful menstrual periods and acute migraine attacks.

DiclacHexal is a prescription medication authorized for the symptomatic management of several conditions involving pain and inflammation. Its primary therapeutic domains include chronic inflammatory joint conditions, such as rheumatoid arthritis, osteoarthritis, and ankylosing spondylitis.

The medication may be an appropriate option for patients seeking relief from pain and stiffness associated with these arthritic conditions. Additionally, it may be used for the short-term management of acute pain states that have an inflammatory component. This can include the symptomatic relief of painful menstrual periods (primary dysmenorrhoea) and the management of acute migraine attacks in adults.

The active substance, diclofenac, is used to reduce inflammation and pain across a wide range of these conditions.

Eligibility Map: Who can and cannot use DiclacHexal — Official Regulatory Information

The eligibility profile for DiclacHexal (systemic Diclofenac) is defined by strict regulatory contraindications, primarily related to cardiovascular, gastrointestinal, and organ health.

Populations for whom use is contraindicated:

• Patients with established cardiovascular disease, including congestive heart failure (NYHA Class II–IV), ischemic heart disease, peripheral arterial disease, or cerebrovascular disease.
• Patients in the setting of Coronary Artery Bypass Graft (CABG) surgery.
• Patients with an active gastric or intestinal ulcer, bleeding, or perforation, or a history of previous NSAID-related gastrointestinal bleeding.
• Patients with severe hepatic or severe renal failure.
• Patients with a known hypersensitivity to Diclofenac, aspirin, or other NSAIDs (which can precipitate asthma, urticaria, or rhinitis).

Eligibility-Related Restrictions:

Elderly patients are eligible but require caution and must be restricted to the lowest effective dose due to increased risk of serious adverse effects. Treatment initiation for patients with significant cardiovascular risk factors (e.g., uncontrolled hypertension, diabetes) should only follow careful consideration.

Interactions with other medicines and products

DiclacHexal (Diclofenac) exhibits numerous officially documented interactions that fall into three main regulatory classes: pharmacodynamic synergy, pharmacokinetic exposure alteration, and renal hemodynamic interference.

Interaction Scope

Official Interaction Statements

The regulatory profile establishes that co-administration with Anticoagulants (e.g., Warfarin) carries a synergistic increase in the risk of serious haemorrhage. Concomitant use with the strong CYP inhibitor Voriconazole causes a significant increase in Diclofenac's systemic exposure (Cmax increased by 114% and AUC by 78%), while use with Lithium may lead to elevated plasma levels due to reduced renal clearance. Interactions with Diuretics and ACE Inhibitors or ARBs may reduce the antihypertensive or natriuretic effect due to interference with renal prostaglandin synthesis. Finally, a specific timing restriction requires Diclofenac to be avoided for 8 to 12 days following Mifepristone administration to prevent reduced efficacy of the latter substance. Ingestion of Alcohol may also increase the risk of gastric irritation and gastrointestinal mucosal bleeding.

Enzymatic Blockade of Prostanoid Synthesis

The mechanism of Diclofenac (the active ingredient in DiclacHexal) centers on the inhibition of Cyclooxygenase (COX) enzymes, specifically COX-1 and preferentially COX-2. The molecule acts as a non-covalent competitive inhibitor, reversibly suppressing the initial molecular step of the Prostaglandin synthesis pathway. This suppression is essential for the synthesis of signaling mediators like Prostaglandin E2 ( PGE2), which are responsible for defining the intensity of local tissue responses.

Modulation of Nociceptive and Systemic Signaling

The resulting reduction in PGE2 concentrations directly results in the modulation of two key physiological systems: nociceptive signaling and local vascular response. By reducing PGE2, the drug prevents the hyper-sensitization of peripheral nerve endings, which are the biological structures responsible for peripheral nociceptor signaling. Concurrently, the modulation of vascular prostanoids contributes to stabilizing blood vessel activity and modulating vascular permeability at the tissue interface. Furthermore, COX inhibition in the Hypothalamus modulates the elevated central temperature set-point.

DiclacHexal, which contains the active ingredient diclofenac, is administered solely via the oral route as tablets, capsules, or powder for solution. A foundational principle guiding its use is the administration of the lowest effective dose for the shortest duration required to address symptoms. The maximum recommended daily dose for chronic maintenance treatment, such as for osteoarthritis or rheumatoid arthritis, is generally 150 mg.

The medicine is supplied in various oral formulations that dictate specific administration rules. Delayed-release and extended-release tablets, commonly 75 mg or 100 mg strengths, must be swallowed whole; they should not be crushed, broken, or chewed to avoid compromising the controlled release mechanism. Dosing frequency varies by form: prolonged-release tablets are typically taken once daily, while standard release tablets often require divided doses two or three times daily.

Administration timing often relates to the type of dose. Immediate-release formulations for acute pain are sometimes instructed to be taken before meals to facilitate rapid absorption. In contrast, the oral powder for acute use must be mixed only with a small amount of water and consumed on an empty stomach. For specific populations, particular caution is indicated: therapy must be initiated at the lowest effective dosage when treating older adults or patients with known hepatic impairment. If a dose is missed, patients are instructed to take the next dose at the usual scheduled time and to avoid taking a double dose.

Evidence for Chronic Inflammatory Joint Conditions

The research base exploring systemic diclofenac in conditions like osteoarthritis and rheumatoid arthritis relies on numerous Randomized Controlled Trials (RCTs) and systematic reviews. These studies examine patient-reported outcomes and metrics related to physical function and pain intensity. Investigators monitored how symptoms evolved in the observed populations by tracking patterns over the trial periods. Regulatory bodies have also analyzed large-scale observational data. What remains uncertain is the durability of the observed patterns over the long term, as the research primarily provides insight into short-term changes.

Research on Acute, Short-Term Pain Management

Research for acute conditions, such as painful menstrual periods and acute migraine attacks, has been conducted using crossover studies and placebo-controlled trials. These studies were relevant in trials assessing short-term or episodic symptom patterns. For painful menstrual periods, studies describe an association between administration timing and reported observations in pain intensity metrics. For acute migraine, trials focused on outcomes such as achieving a pain-free status within two hours. In both contexts, follow-up durations were limited, focusing on the immediate symptom phase, and data are still emerging regarding the variability of response beyond the immediate episode.

Studies in Specific Groups and Evidence Gaps

Systemic diclofenac was evaluated in specific patient groups, including older adults with chronic conditions. Data for pediatric populations (adolescents) are more limited, and the overall evidence remains insufficient to characterize outcomes related to symptom change. Furthermore, a review highlights several areas where certainty remains low. Follow-up durations were limited in many controlled studies, meaning that the long-term effects are not fully established. The research provides context but not individual predictions, as study results reflect the specific conditions under which they were conducted.

Key Studies & References Safety review of diclofenac - Therapeutic Goods Administration (TGA)

How to Store and Dispose of DiclacHexal?

Official regulatory guidelines define specific conditions for storing DiclacHexal (diclofenac sodium oral tablets) to maintain product stability and ensure environmental safety during disposal.

Storage Requirements

Disposal Instructions

Expired or unused DiclacHexal must be discarded according to local regulatory waste instructions. To prevent environmental contamination, the product should not be disposed of in wastewater or released into sewers or groundwater. Disposal should occur through an approved waste disposal method or drug take-back program.